Life Sciences Archive » March, 2015

Life Sciences - March, 2015

326 articles

• 11th Circ. Backs Bard In Vein Filter Product Liability Row
• Insmed To Issue $206M In Stock To Fund Inhaled Antibiotics
• Migraine Biotech Heads For $86M IPO With Alternative Drug
• FDA Issues Strongest Warning On Intravenous Anemia Drug
• Cephalon Wants FCA Off-Label Marketing Claims Axed
• Ex-Merck VP Says Investors 'Overstate' Omnicare Impact
• Ranbaxy, AstraZeneca Say Plaintiffs Lack Basis For New Trial
• Fed. Circ. Revives Generic Benicar Exclusivity Challenge
• GSK Urges 3rd Circ. To Nix $121M Damages In Paxil Row
• Biosimilar Patent Disputes — An Update On The Last 8 Months
• Axed Trustees Of Herbalife Founder's Estate Still Fired
• J&J Units, Glaxo Settle False Ad Suit Over Flonase Claims
• Patent For Robotic Pill Dispensing System Ruled Invalid
• Otsuka-FDA Row Tests Potent Anti-Generic Tool
• The 2015 Rising Stars, By Firm
• GNC Deal May Push Retailers To Boost Supplement Testing
• Monsanto, Pfizer Beat PCB Contamination Cost Suit
• EU Requires Antitrust Fixes On $13.4B Zimmer-Biomet Deal
• Novartis, Aduro Ink $750M Cancer Drug Development Deal
• Horizon Pharma To Buy Hyperion Therapeutics For $1.1B
• Bristol-Myers Faces Retaliation Suit After FCA Claims Axed
• Purdue's Sleep Aid Patents Are Obvious, Judge Rules
• FDA Can't Revoke Ranbaxy's Drug Approvals, DC Circ. Told
• MultiVir Eyes Float Amid Stream Of Cancer-Focused IPOs
• Ranbaxy Can't Nix Glass-Tainted Pill Class Action
• Teva To Buy US Biotech Auspex Pharma In $3.2B Drug Merger
• High Court Won't Hear Pliva's Generic Preemption Case
• Mediation And The Thorny Issue Of Settlement Authority
• Teva Impact Will Depend On Phillips Hierarchy Of Evidence
• DOJ Investigation Into Generic Pharma: You Could Be Next
• A-Rod's Cousin Pleads Guilty In MLB Doping Scandal
• Provigil Pay-For-Delay Suit Survives Reconsideration Bid
• Sandoz Can't Dodge Cancer Drug Product Liability Suit
• Insurers Won't Pay For Biotronik's $28M Pacemaker Suit
• Spectrum Pharmaceuticals Stuck With Shareholder Suit
• Medical Products Distributor HSI Protests $68M Tax Bill
• FDA Hears Wide Debate On Generic-Drug Warning Label Plan
• Plaintiffs Blast BioScrip's Use Of Omnicare In Shareholder Suit
• Glucosamine Class Can't Back Out Of $5M Deal, Judge Says
• Law360 Names Top Attorneys Under 40
• GSK Says Calif. Court Should Oversee Abbott HIV-Drug Suit
• Reed Smith Atty To Testify On Novartis Kickback Advice
• Biomet Again Underscores FCPA Risks In Life Sciences
• What Experts Can Say About Inadmissible Facts During Trial
• False Ads Juicing Up Rival's Profits, Supplement Co. Says
• Fed. Circ. Shields Some Patent App Revivals From APA Review
• GNC Asks JPML To Split Supplement MDLs, Consolidate In Pa.
• Deals Rumor Mill: SoftBank, Evonik, Union Bancaire
• Walgreen, Others Sue Over Opana, Solodyn Generic Deals
• Millennium Beats Off-Label Suit, But Free Speech No Factor
• FDA Approves Emergent's Inhalation Anthrax Treatment
• Omnicare Bolsters Case Against Ex-Merck VP, Investors Say
• FDA Rejects Amgen's Biosimilars Info-Sharing Petition
• FedEx Tries To Buck Charges Of Drug Shipping Conspiracy
• Walgreen, Others Sue Over Alleged Aggrenox Pay-For-Delay
• 11th Circ. Won't Revive Chinese Pharma Class Action Claims
• ZS Pharma Eyes $214M Offering To Commercialize Lead Drug
• Ariad, Execs Beat Fraud Suit Over Failed Leukemia Drug
• Utah Bill Targeting Contact Lens Pricing Awaits Gov.'s OK
• Alps Asks Fed. Circ. To Affirm Inequitable-Conduct Ruling
• Kilpatrick Townsend Faces Leaner Drug Device IP Theft Suit
• SEC Nets $18M From Drug Co. Accused Of Duping Investors
• FaegreBD Nabs 9 Partners To Amp Up Chicago Operations
• Jones Day-Led Cellectis Outshines Expectations In US IPO
• High Court May Take On Corporate 5th Amendment Privilege
• FDA Widened Abilify Scope To Admit Generics, Otsuka Says
• Class Cert. Denied In Cephalon Painkiller Marketing Suit
• And Now A Word From The Panel: Just Say No (To MDLs)?
• Supplement Co. Throws Flag On NFL Agent's Double-Dealing
• Cellectis Boosts IPO Target As Immunotherapy Cos. Rally
• Goodwin Procter Leads Blueprint Medicines Toward $100M IPO
• Bristol-Myers Picks Up Autoimmune Research Program
• 3rd Circ. Won't Rehear Relator's FCA Suit Over Drug Costs
• Pharma Patent Rules Give FTC Too Much Clout, DC Circ. Told
• Attys Want 33% Slice Of $1M Pie In PolyMedix Stock Suit
• Biomet's DPA Proves An Inescapable Device
• BPCIA: How Long Is The Party, And Do I Have To Dance?
• Teva, Boehringer Trim 'Frankensteinian' Aggrenox Claims
• DaVita Dodges Dialysis Products Claims
• Pliva Urges Justices To Overturn Iowa Court Generics Ruling
• SEC Says Convicted Atty In NFLer Scam Can't Revisit Ruling
• Deals Rumor Mill: World Duty Free, Warburg Pincus
• Liberty Reaches Deals To Exit Sprawling Meningitis Row
• Contempt Sought In $150M Chinese Vitamin C Antitrust Case
• Patent Troll Bill Embraces 'Political Realism,' Rep. Says
• Fed. Circ. Clips Exela Appeal In Ofirmev Infringement Row
• Contact Lens Antitrust Suits Linked Up In Calif. Court
• USPTO Judge Says Successful IPR Cases Potentially Problematic
• Philly Plaintiffs Free Auxilium From Testim Warranty Claims
• 2 Scientists Guilty Of $10M Gov't Research Grant Fraud
• J&J Wins Battle Over Concerta Patent Ownership
• High Court Won't Hear Stiefel Appeal In $1.5M Share Fight
• Latham & Watkins Adds Another Ex-Finnegan Life Sci Pro
• HHS Fights Court Review In 340B Orphan Drug Row
• 3 Factors Driving The Pharma M&A Surge
• High Court Dumps 1 Of 3 Pa. Reglan Preemption Petitions
• The Law360 400
• A Texas Court's Broad Reading Of FCA Public Disclosure Bar
• Litigation Firms Make Cuts Amid Work Slowdown
• Is MegaLaw Just Big Enough To Fail?
• Law360 Reveals 400 Largest US Firms
• Juror's Google Search May Trigger New Tylenol Death Trial
• Cooley, Maynard Cooper Lead Sluggish Week's 2 IPOs
• Olympus America Hit With 'Superbug' Exposure Suit
• Gilead Attacks FCA Suit's Claims Of Shoddy Drugmaking
• 8 IPOs On Deck To Shatter Lull In New Issuances
• 3 Things To Watch After Sandoz's Biosimilars Win
• FTC To Send Refunds To Body Slimming Cream Customers
• Re-Exam Can't Save Allergan Eye Drop IP, Fed. Circ. Says
• Effexor Buyers Fight To Keep Appeal In 3rd Circ.
• Aveo Kicks Investor Suit Over Losses From Kidney Drugs
• Irish Biotech Malin Raises $357M In IPO For Acquisitions
• 5 Federal Tax Planning Tips For Marijuana Businesses
• Pharmaceutical Co. SteadyMed Misses Target With $40M IPO
• 5 New FCA Rulings Attys Need To Know
• J&J Dodges Claims In 2nd Philly Risperdal Trial
• Gilead Under Fire Again Over New Hepatitis C Program
• Medical Device Companies Face Increased TAA Scrutiny
• Lewis Brisbois Adds IP And Tech Atty To Denver
• 5 Insights From Avon General Counsel Jeff Benjamin
• Another Suit Targets Blood Thinner Xarelto For Side Effects
• Darvocet Plaintiffs Want Suits Sent Back To California
• Sandoz Beats Amgen Bid To Delay Biosimilar Competition
• Heart Monitor Co. To Pay $6.4M To Avoid FCA Overbilling Suit
• Provigil Buyers Drop Fight Over Teva Off-Books Deals
• J&J Buys UK Biopharma Co. To Bolster Cardiovascular Line
• Bristol-Myers Hits Mylan With Suit Over Generic HIV Drug
• Second Philly Risperdal Mass Tort Case Heads To Jury
• FTC, Abbvie Tussle Over Discovery In Pay-For-Delay Suit
• FCA Whistleblowers Poised To Target Post-Employment Fraud
• NJ Supreme Court Clarifies Expert Testimony Rule
• Marshall Gerstein Reels In IP Atty, Technical Specialist
• Post-Grant Proceedings Are Important For Biosimilars
• J&J Unit Stuck With $10M Children's Motrin Verdict
• FTC Backs Christian & Barton Atty For Reckitt Master
• Fed. Circ. Upholds Smith & Nephew's $95M Suture Patent Win
• Ex-NFL Star Gets Mixed Verdict In SEC Pump-And-Dump Suit
• Deals Rumor Mill: Zimmer Holdings, Blackstone Group, Ocwen
• Cancer Treatment Developer Cellectis Fine-Tunes $130M IPO
• Sandoz Gets Investor Suit Over Oriel Buyout Trimmed
• Justices Told $5M IP Award Must Stand Despite Reversal
• DOJ Monitors Biomet For Another Year For FCPA Violations
• Epizyme Eyes $124.5M Offering After Buying Back Cancer Drug
• Cooley Nabs 3 PE, Life Sciences Pros For London Outpost
• Lack Of Off-Label Causation Analysis Could Be Costly
• Valeant Plans $1.45B Stock Offering To Fund Salix Buy
• Teva Will Increase Reliance On Experts In Patent Cases
• Bristol-Myers Gets Relators Booted In Calif. Kickback Suit
• Mass. Beats Most Zogenix Claims Over Painkiller Regulation
• OPINION: Not All That Is Public Should Be Publicized
• Amarin Says FDA Changed Rules To Deny Market Exclusivity
• 2 Drug Developers Latest To Tap Market With $275M On Offer
• Novartis Escapes FCA Suit Over Xolair Marketing
• GSK Found No Asthma Deaths From COPD Drug, FDA Reports
• Merck KGaA Places $4B In Bonds To Fund Sigma-Aldrich Buy
• Contact Lens Cos. Seeing Double As Conspiracy Suits Pile Up
• Drug Giants Commit To $100M Dementia Research VC Fund
• Ex-Employees Accuse Novartis Unit Of Sex Discrimination
• Vital Settles Energy Drink Claims For Price Of 1 Beverage
• Lipitor Buyers Can't Update Pay-For-Delay Suit Again
• Herbalife Investor Suit Crumbles Under Causation Standard
• Life Sciences Cos. See Jump In Securities Suits, Dechert Finds
• Fed. Circ. Will Hear Mylan Hatch-Waxman Jurisdiction Case
• Pfizer's $400M Class Action Settlement Gets Early Nod
• Zimmer Names 3 Bellwether Cases In Knee Implant MDL
• Fed. Circ. Junks $61M Enzo Win In DNA Patent Suit
• 4th Circ. Revives Chelsea Therapeutics Class Action
• National Union Seeks Quick Win In $100M Coverage Dispute
• 3 Ways Valeant Turned Allergan Misfire Into Salix Victory
• Bipartisan House Votes To Speed Up Drug Scheduling
• FTC Says Study Documents Aren't Needed In Actavis Case
• Sandoz Paying $12.6M In Medicare Drug Pricing Dispute
• Pa. Superior Court Affirms $11M Topamax Ruling
• Vitamin Shoppe Says Falsely Labeled Product Doesn't Exist
• IMS Rolls Out €275M Note Offering To Back Cegedim Deal
• Promega: Can Inducer And Infringer Be The Same Party Now?
• Valeant Wins Salix Battle After Upped Bid Makes Endo Bow Out
• IP Boutiques Shrink Amid Litigation Slowdown
• Cancer-Focused Biotechs ViewRay, Xbiotech Join IPO Rush
• Week's Lone IPO Nets $400M As 7 Cos. Promise To Break Lull
• Sandoz ACA Violation Unlikely In Amgen Suit, Judge Says
• Valeant To Raise Salix Offer In Wake Of Endo's Bid
• J&J Units Claim Glaxo Falsely Markets Allergy Med
• Law360's Product-Hopping Cheat Sheet For 2015
• 2nd Circ. Product-Hopping Ruling May Prompt More Suits
• Ackman Says He Didn't Break Law In Anti-Herbalife Campaign
• Judge Bars New Claims In Brown Rudnick Malpractice Row
• PE-Backed Par Pharmaceutical Plans $700M IPO
• Valeant Prices $10.1B Bond Offering To Help Fund Salix Deal
• 5 Insights From Dish General Counsel Stanton Dodge
• Sealed, Signed, Delivered: End Of Mail-Order Pharmacies?
• Execs Name Top Industry Risks In 2015
• J&J, Bard Trial Settlements Show Mesh MDL's Growing Pains
• Experts Limited To 3 In Bard Pelvic Mesh Cases
• Herbalife Rips Ackman's $1B Bet Amid News Of Criminal Probe
• Insurer Gets Fake-Pot Co.'s Policy Rescinded
• 4 Ways Sullivan & Cromwell Can Talk Up Valeant's Salix Bid
• Aduro Becomes Latest Immuno-Oncology Biotech To Plan IPO
• Market Rumors: Integrated Dental, Weststar, Valeant
• FDA Gives Guidance On Cleaning Superbug Scopes
• Hagens Berman Faces Probe Of Thalidomide Client Dismissal
• Big-Name VCs Inject $80M Into Peanut Allergy Treatment
• The 'Palmetto Put-Down' Endangers Drug Cos. Nationwide
• OPINION: Beyond The 'Grow Or Die' Law Firm Model
• Class Action Over Bayer's One-A-Day Labeling Survives
• Mayer Brown, Davis Polk Steer Abbott's $2.5B Notes Offering
• Teva Fights Provigil Attys Over Shielding Settlement Fees
• Jones Day Says Sanctions In Abbott Suit Were Biased
• FDA Beats Ranbaxy Suit Despite 'Serious' Approval Errors
• Texas Pharma Co. Agrees To Pause Drugmaking After Recall
• Judge Issues Rare Injunction In CR Bard Unit's Patent Case
• Kythera Prices $125M Offering After Double-Chin Drug OK'd
• CORRECTED: Report Details $2.3B In 2014 Health Fraud Recovery
• Bidvest, PIC Scope Out Joint Bid For S. African Pharma
• Tracking The Likelihood Of Liability From Health Apps
• Bayer To Spin Off Or List $10B Polymer Biz By 2016
• Endo Confirms $10.6B Salix Bid, Besting Valeant Offer
• Columbia Labs Investors Can't Revive Class Suit In 3rd Circ.
• Zimmer Launches $7.65B Bond Sale To Back Biomet Buy
• VisionAid Insurer Off Hook For Counterclaims In Firing Suit
• Reckitt Must Hand Over Nonprivileged Suboxone Docs To FTC
• FDA Chides Discovery Labs For Dissing Animal Products
• Nutter McClennen Grows IP Practice With Life Sciences Hire
• Ethicon Settles Bellwether Pelvic Mesh Case Mid-Trial
• Dow Corning Asks 6th Circ. To Rehear Breast Implant Suit
• Deals Rumor Mill: KKR, Voith, Dr. Reddy's
• Provigil Attys Look To Shield Fees In Teva Settlements
• Law360 Life Sciences Editorial Advisory Board
• J&J Unit Pleads Guilty Over Children's Tylenol Recall
• State AGs Cracking Down On Herbal Supplement Industry
• Bayer Rice MDL Attys Fight To Keep Fee Class Action Alive
• AltheaDX Nixes IPO As 3 Other Diagnostic Cos. Eye Debuts
• Biopharma Co. Didn't Lie About Cancer Drug Progress: Judge
• 2 Life Sciences Cos. Set Terms Amid Quiet Period For IPOs
• FDA Issues Warning On Seizure, Alcohol Risk With Chantix
• Clearing The Smoke Around The Farr-Rohrabacher Amendment
• Herbalife Says Investor Suit 'Slavishly' Parrots Ackman
• Hagens Berman Leads Suit Alleging Merck Hid Suicide Risks
• Medtronic Hit With FCA Retaliation Suit By Fired Sales Rep
• Ariad Directors Beat Investor Suit Over Failed Leukemia Drug
• Contact Lens Cos. Face Collusion Suit From Indirect Buyers
• GE Shakes Imaging Drug Deal Antitrust Suit In 9th Circ.
• Nicholson & Eastin Can't Rep FCA Whistleblowers, Judge Says
• HHS Watchdog Pressed On New Health Fraud Safe Harbors
• Insurers Needn't Defend Anda In W.Va. 'Pill Mill' Suit
• Ex-U. Miami Coach To Plead Guilty In Doping Case
• Hagens Berman Sanctioned For Bad Thalidomide Suits
• 3rd Circ. Urged To Rehear FCA Suit Over Drug Costs
• Ackman Bets $3B On Former Buyout Partner Valeant
• High Court Asked To Review After-Acquired Evidence Use
• Hedge Fund's AIA Attack Should Have Biotech Cos. Wary
• Concordia Puts Up $1.2B For PE-Backed Drugmaker
• Early Lessons From The REMS Battlefield
• Amazon Sued Over Teen's Death From Caffeine Overdose
• FTC Orders Divestitures In Impax's $700M CorePharma Buy
• Pharm Co. Plans to Appeal Class Cert. In Antitrust MDL
• March Starts Quietly With 2 IPOs, But Forecast Still Strong
• Contact Lens Pricing Suits To Test Landmark Leegin Case
• Taxation With Representation: Wachtell, Gibson, Baker
• 3rd Circ. Declines To Hear Mylan, Celgene Antitrust Fight
• Genentech Blood Cancer IP Not Double-Patented, Judge Rules
• J&J Unit Urges Fed. Circ. To Revive Covidien Patent Suit
• TWi Tells Fed. Circ. Takeda's Dexilant Patent Claims Are Invalid
• Developer Must Face Pisgah's $100M Anti-Abuse Vicodin Suit
• FDA Approves 1st Biosimilar But Punts On Naming Guidance
• The Daimler Confusion And Its Impact On ANDA Litigation
• Suspect In MLB Doping Scandal Moves To DQ Atty
• 5 Tricky Questions To Test Your Drug-Label Law Savvy
• J&J, Ethicon Hit For $5.7M In Calif. Pelvic Mesh Trial
• Bard Tells Fed. Circ. Not To Eye Willfulness In $1B IP Case
• Akorn Hid Delays Integrating VersaPharm, Shareholder Says
• Martek Escapes Injunction In Baby Formula Antitrust Suit
• Paul Hastings Hires Co-Head Of Fried Frank's M&A Practice
• Walgreens, Safeway Want To Join Lidoderm MDL
• USTR Prods 'Notorious' Piracy Markets To Reform
• Intercept Can't Dodge Investors' Stock Drop MDL
• Spain Probes Pfizer For Blocking Parallel Imports
• Fried Frank Hires Ex-Patterson Belknap IP Pro In NY
• Aussie Consumer Watchdog Probes OTC Pain Meds
• Gilead Digs In For High Court Double-Patent Appeal
• Ohio Gets Help In Heroin Epidemic With Rebates On Treatment
• Growth-Minded AMAG Pharma Closes $201.2M Stock Offering
• Mallinckrodt Puts Up $2.3B For PE-Backed Lung Drug Outfit
• A Riegel Analysis From The Great Northwest
• Law Firm Tensions Mount In Africa — What Does It Mean?
• Wachtell Guides AbbVie In $21B Pharmacyclics Buy
• Teva Gets Warner Chilcott's Atelvia Patents Invalidated
• Provigil Buyers Say Teva Coercing Distributors To Pare Suit
• NJ Patent Suits Jump As Pharma Cos. Battle Closer To Home
• Celgene Hit With Suit For Blocking Generic Cancer Drugs
• Novartis Told To Produce Docs In Kickbacks Suit By March 13
• Jones Day Scoops Ex-Roetzel FDA Pro In Miami
• Sanofi Pushes 3rd Circ. To Toss Junk Fax Class Action
• Blackstone-Backed Catalent Eyes $699M In Upsized Offering
• Takeda Dodges Doc Destruction Claims In Wis. Actos Suit
• J&J, Others Sued Over Alleged Contact Lens Price Floors
• 5th Circ. Says Paxil Heart Damage Suit Brought Too Late
• Cleary Gottlieb Leads Actavis In $21B Debt Offering
• How Mayo, Myriad And Alice May Impact Patent Valuations
• Calif. Appeals Court Upholds Breg Win In Pain Pump Suit
• Paul Weiss Rips Med. Co. Liquidator Push For Privileged Docs
• Patent Vet Jumps From Frommer Lawrence To Garson Segal
• EU High Court To Weigh Antitrust Limits To Patent Deals
• FCPA Self-Reporting Brings Benefits: SEC Enforcement Chief
• 2nd Circ. Agrees To Speed Actavis Product-Hopping Hearing
• Med Device Maker Stryker Boosts Share Buybacks To $2.6B
• DOD Awards $430M Surgical Robotics Contract
• Market Rumors: Actavis, HKBN, Aldermore
• Recruiter For Miami Doping Scandal Sentenced To 3 Months
• Viking Recalibrates Drug Focus In New IPO Plans
• FDA Slaps New Warnings On Testosterone Drugs
• The FDA's Vision For Medical Devices Is Coming To Life
• 4th Circ. Upholds J&J Win In Vaginal Mesh Bellwether Case
• Pharmas Fail To Nix Cohen Milstein's Contract With Chicago
• Supplement Maker Vitacost Settles Workout Drink Patent Tiff
• Fed. Circ. Lops Lost Profits Off $101M Medtronic Patent Verdict
• PacWest Ponies Up $849M In Stock For Square 1
• Costco Says J&J Blocked Contact Lens Discounts
• Cygnus Urges Fed. Circ. To Revive Medtrica Patent Row
• Panel Tosses Law Firm's SLAPP Defense To Malpractice Claim
• J&J May Continue Divestiture Trend With $2B Cordis Offer
• Billion-Dollar Issues Loom Over Fla. Legislature Session
• J&J Unit LifeScan Settles Diabetes Product Patent Dispute
• Boston Scientific To Pay $1.6B For Endo Urology Portfolio
• Judge Nixes Class Cert. In Vital Redline Energy Drink Suit
• Actavis Plots Another Offering To Back $66B Allergan Deal